Invention Grant
- Patent Title: Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
-
Application No.: US14840528Application Date: 2015-08-31
-
Publication No.: US09642855B2Publication Date: 2017-05-09
- Inventor: Paul Galatsis , Matthew Merrill Hayward , Bethany Lyn Kormos , Travis T. Wager , Lei Zhang , Antonia Friederike Stepan , Jaclyn Louise Henderson , Ravi G. Kurumbail , Patrick Robert Verhoest
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent John A. Wichtowski
- Main IPC: A61K31/519
- IPC: A61K31/519 ; C07D487/04 ; A61K31/5377 ; C07D519/00
![Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors](/abs-image/US/2017/05/09/US09642855B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
Public/Granted literature
- US20150366874A1 Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors Public/Granted day:2015-12-24
Information query
IPC分类: